|
Daily Medical Update
Primary Headache Disorders
Wednesday, April 01, 2026
|
🔬 Practice‑Changing Findings
Evidence from RCTs and meta‑analyses published in the last 12 months.
|
Neurology (2026) - Phase 4 Randomized Controlled Trial
Key Findings
- Monthly migraine days over weeks 1-4 fell by 6.9 days with eptinezumab plus brief education versus 3.7 days with placebo plus education, for a between-group difference of 3.2 days (95% CI 2.2-4.2; p < 0.0001).
- Monthly headache days, acute migraine medication-use days, and average daily pain all improved significantly with eptinezumab, and the greater reduction in burden was sustained through weeks 1-12.
- Treatment-emergent adverse events were similar with eptinezumab and placebo (41.9% vs 36.9%), and no new safety signals were identified.
📋 Practice Implication: For chronic migraine complicated by medication overuse, clinicians can consider starting eptinezumab alongside structured education instead of delaying preventive treatment until complete withdrawal of acute medications is achieved.
|
Annals of Medicine (2026) - Systematic Review and Network Meta-Analysis
Key Findings
- Amitriptyline 100 mg reduced monthly headache days more than placebo at 4 weeks (MD -6.59, 95% CrI -11.22 to -0.64) and 8 weeks (MD -6.14, 95% CrI -10.27 to -0.87).
- Amitriptyline 100 mg was the highest-ranked treatment for monthly headache-day reduction at 4, 8, and 24 weeks, while lidocaine 25 mL ranked highest at 12 weeks.
- Higher adverse event rates vs placebo were seen with amitriptyline 100 mg and BTX-A 500 U.
📋 Practice Implication: For patients who need preventive pharmacotherapy for chronic tension-type headache, amitriptyline remains the practical first-line benchmark, but its adverse-effect burden should be weighed before dose escalation.
|
BMC Neurology (2026) - Systematic Review and Meta-Analysis
Key Findings
- CGRP antagonists reduced weekly cluster headache attacks by a mean of 7.23 attacks (95% CI 4.60-9.86 fewer).
- The pooled responder rates were 46% for at least 50% reduction in weekly attacks and 59% for at least 30% reduction, with larger effects in episodic than chronic cluster headache.
- Serious adverse events were uncommon at 4%, and treatment discontinuations were uncommon at 3%.
📋 Practice Implication: In refractory cluster headache, CGRP antagonists are reasonable to consider after standard options fail, especially in episodic disease, but expectations should remain cautious until larger long-term trials clarify durability and comparative benefit.
|
|
Recent evidence across primary headache disorders is most actionable in preventive care: a phase 4 trial supports eptinezumab plus brief education for chronic migraine with medication-overuse headache, a network meta-analysis keeps amitriptyline as the best-supported drug prophylaxis for chronic tension-type headache, and a meta-analysis suggests CGRP antagonists can reduce attack burden in cluster headache. Taken together, the strongest signal is to individualize treatment by headache subtype while recognizing that cluster headache data remain supportive rather than definitive and medication tolerability still limits prophylaxis choices.
|
|